Blood Res.  2022 Dec;57(4):272-277. 10.5045/br.2022.2022153.

FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group

• Chozie NA
• Gatot D
• Sudarmanto B
• Susanah S
• Purnamasari R
• Widjajanto PH
• Nugroho S
• Rasiyanti O
• Puspitasari D
• Riza M
• Shanty Larasati MC
• Adiyanti SS
• Saraswati MC
• Primacakti F
• on behalf of the Pediatric Hematology-Oncology Working Group of the Indonesian Pediatric Society

• KMID: 2537550
• DOI: http://doi.org/10.5045/br.2022.2022153

Abstract

Background
Factor VIII (FVIII) inhibitor diagnosis and surveillance in Indonesia are challenging owing to geographic conditions and the lack of laboratory facilities nationwide for inhibitor assays. This study aimed to determine the prevalence of FVIII inhibitors in children diagnosed with hemophilia A (HA) in Indonesia.
Methods
A cross-sectional study was conducted in 12 hospitals in eight provinces of Indonesia between 2020 and 2021. Factor VIII inhibitor screening was performed in a central hemostasis laboratory for all children with HA (≤18 yr) who had received a minimum of 10 exposure days to clotting factor concentrates. The FVIII inhibitor titer was determined using the Bethesda assay.
Results
Children (388) were enrolled in this study, including 219 (56.4%), 131 (33.8%), and 38 (9.4%) with severe, moderate, and mild HA, respectively. The prevalence of children who developed FVIII inhibitors was 37 out of 388 (9.6%). Factor VIII inhibitors were found in 25/219 (11.4%) severe, 11/131 (8.3%) moderate, and 1/38 (2.6%) children with mild HA. Thirteen children had low-titer inhibitors and 24 had high-titer inhibitors, with a median of 9.44 (1.48‒412.0) Bethesda Units. Among 13 children with low-titer inhibitors, eight underwent a confirmation test, of which five tested negative and were classified as transient. A significant difference in annual joint bleeding rate was found between patients with low and high inhibitor titers and those without inhibitors (P ＜0.001).
Conclusion
Factor VIII inhibitor prevalence in Indonesia was relatively low. However, the risk factors that may contribute to FVIII inhibitor development among Indonesian patients require further study.

Keyword

Inhibitor; Factor VIII; Hemophilia A

Figure

• 

  Fig. 1 Results of inhibitor surveillance among patients (N=388).

Reference

1. Srivastava A, Santagostino E, Dougall A, et al. 2020; WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 26:1–158. DOI: 10.1111/hae.14046. PMID: 32744769.

2. Carcao M, Goudemand J. 2018. Inhibitors in hemophilia: a primer. 5th ed. World Federation of Hemophilia;Montréal, Canada: at http://www1.wfh.org/publication/files/pdf-1122.pdf. Accessed November 29, 2021.

3. Villarreal-Martínez L, García-Chávez J, Sánchez-Jara B, et al. 2020; Prevalence of inhibitors and clinical characteristics in patients with haemophilia in a middle‐income Latin American country. Haemophilia. 26:290–7. DOI: 10.1111/hae.13951. PMID: 32141696.

4. Ljung R, Auerswald G, Benson G, et al. 2019; Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients. Eur J Haematol. 102:111–22. DOI: 10.1111/ejh.13193. PMID: 30411401. PMCID: PMC6936224.

5. Garagiola I, Palla R, Peyvandi F. 2018; Risk factors for inhibitor development in severe hemophilia A. Thromb Res. 168:20–7. DOI: 10.1016/j.thromres.2018.05.027. PMID: 29879570. PMCID: PMC6055565.

6. Mancuso ME, Fischer K, Santagostino E, et al. 2017; Risk factors for the progression from low to high titres in 260 children with severe haemophilia A and newly developed inhibitors. Thromb Haemost. 117:2274–82. DOI: 10.1160/TH17-01-0059. PMID: 29212115.

7. Peyvandi F, Cannavò A, Garagiola I, et al. 2018; Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 16:39–43. DOI: 10.1111/jth.13888. PMID: 29080391.

8. Peyvandi F, Garagiola I. 2018; Product type and other environmental risk factors for inhibitor development in severe hemophilia A. Res Pract Thromb Haemost. 2:220–7. DOI: 10.1002/rth2.12094. PMID: 30046724. PMCID: PMC6055565.

9. Collins PW, Palmer BP, Chalmers EA, et al. 2014; Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood. 124:3389–97. DOI: 10.1182/blood-2014-07-580498. PMID: 25339360. PMCID: PMC4246037.

10. Peyvandi F, Kavakli K, El‐Beshlawy A, Rangarajan S. 2022; Management of haemophilia A with inhibitors: a regional cross‐talk. Haemophilia. 28:950–61. DOI: 10.1111/hae.14638. PMID: 35868021.

11. Volkers P, Hanschmann KM, Calvez T, et al. 2019; Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: combined analysis of three studies. Haemophilia. 25:398–407. DOI: 10.1111/hae.13747. PMID: 31066174.

12. Gouw SC, van der Bom JG, Ljung R, et al. 2013; Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 368:231–9. DOI: 10.1056/NEJMoa1208024. PMID: 23323899.

13. Adcock Funk DM, Lippi G, Favaloro EJ. 2012; Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost. 38:576–85. DOI: 10.1055/s-0032-1319768. PMID: 22706973.

14. Kitchen S, Adcock DM, Dauer R, et al. 2021; International Council for Standardization in Haematology (ICSH) recommendations for processing of blood samples for coagulation testing. Int J Lab Hematol. 43:1272–83. DOI: 10.1111/ijlh.13702. PMID: 34581008.

15. Schep SJ, Boes M, Schutgens REG, van Vulpen LFD. 2019; An update on the 'danger theory' in inhibitor development in hemophilia A. Expert Rev Hematol. 12:335–44. DOI: 10.1080/17474086.2019.1604213. PMID: 30951401.

16. Meeks SL, Batsuli G. 2016; Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology Am Soc Hematol Educ Program. 2016:657–62. DOI: 10.1182/asheducation-2016.1.657. PMID: 27913543. PMCID: PMC6142469.